Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer

BACKGROUND: Immune Modulation and Gemcitabine Evaluation-1, a randomised, open-label, phase II, first-line, proof of concept study (NCT01303172), explored safety and tolerability of IMM-101 (heat-killed Mycobacterium obuense; NCTC 13365) with gemcitabine (GEM) in advanced pancreatic ductal adenocarc...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Br J Cancer
Hoofdauteurs: Dalgleish, Angus G, Stebbing, Justin, Adamson, Douglas JA, Arif, Seema Safia, Bidoli, Paolo, Chang, David, Cheeseman, Sue, Diaz-Beveridge, Robert, Fernandez-Martos, Carlos, Glynne-Jones, Rob, Granetto, Cristina, Massuti, Bartomeu, McAdam, Karen, McDermott, Raymond, Martín, Andrés J Muñoz, Papamichael, Demetris, Pazo-Cid, Roberto, Vieitez, Jose M, Zaniboni, Alberto, Carroll, Kevin J, Wagle, Shama, Gaya, Andrew, Mudan, Satvinder S
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Nature Publishing Group 2016
Onderwerpen:
Clinical Study
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5046215/
https://ncbi.nlm.nih.gov/pubmed/27599039
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2016.271
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items